MNKD Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
MannKind Corp (MNKD) does not present a compelling buy opportunity for a beginner investor with a long-term strategy at this time. While there are positive catalysts such as Afrezza's pediatric approval and potential revenue growth avenues, the lack of recent AI Stock Picker or SwingMax signals, hedge fund selling, and mixed analyst ratings suggest a cautious approach. The technical indicators and options sentiment are neutral to slightly positive, but not strong enough to justify a buy recommendation.
The MACD is positive at 0.0281, indicating mild bullish momentum, but it is contracting. The RSI at 67.817 is neutral, showing no clear overbought or oversold conditions. Moving averages are converging, suggesting indecision in the market. Key resistance levels are at 3.974 and 4.135, while support levels are at 3.455 and 3.294.
Afrezza's approval for pediatric use and upcoming PDUFA dates for Furoscix and MNKD-201 could drive future growth. Analysts have raised price targets citing royalty durability and pipeline potential.
Hedge funds are selling, with a significant 337.78% increase in selling activity over the last quarter. No recent news or congress trading data to support bullish sentiment. Mixed analyst ratings and price target adjustments reflect uncertainty.
No financial data available for the latest quarter, making it difficult to assess the company's growth trends or financial health.
Analysts are mixed. Wells Fargo and H.C. Wainwright raised price targets to $10-$11, citing Afrezza's approval and pipeline potential. However, Mizuho and Truist lowered price targets to $6-$8, reflecting cautious optimism and sector-wide adjustments.
